Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 18, 2024Neuro-OncologyOpen Access

Lmic-27. Mek Inhibitors in Pediatric Low-Grade Gliomas (Plgg)- Early Experience in a Resource Limited Setting

View Full Paper
Ask AI
Bookmark
Share

Authors

GCGirish ChinnaswamyVGVenkata Rama Mohan GollamudiACAmit Choudhari

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chinnaswamy et al. (2024) studied this question.

synapsesocial.com/papers/68e643d5b6db6435875d51cdhttps://doi.org/10.1093/neuonc/noae064.744
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ID #972 Response to combined MEK and mTOR inhibition in refractory pediatric low-grade gliomas: a limited case series2026
  2. 2ID #515 TRAM-01: A Phase 2 study of trametinib for patients with pediatric low grade glioma with activation of the MAPK/ERK pathway.2026
  3. 3BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country2024 · 14 citations
  4. 4ID #58 A NATIONWIDE EVALUATION OF MAPK INHIBITORS FOR PAEDIATRIC LOW-GRADE GLIOMA IN THE UNITED KINGDOM: SAFETY, EFFICACY, VISUAL MORBIDITY, AND OUTCOMES.2026
  5. 5LGG-04. TRAMETINIB COMBINED WITH CHEMOTHERAPY FOR INFANT BRAF-FUSED CHIASMATIC GLIOMA2024